Is AstraZeneca’s Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
AstraZeneca (NYSE:AZN | AZN Price Prediction) reports third-quarter results on Friday, October 30. Farxiga generics are cutting into sales, and a major cardiology trial has failed. This report shows whether oncology and new launches can still carry growth.
Oncology Strength Meets a Bruised Cardio Franchise
Last quarter, revenue reached $15.38B, up 6.4% year over year but slightly short of the $15.42B consensus. Core EPS of $2.63 beat expectations again, and core operating margin expanded 2 points to 34%.
The product mix explains the quarter. Oncology grew 15% to $6.71B, led by Imfinzi (+27%) and Enhertu (+47%). Over the same stretch, Farxiga fell 16% after U.S. generics arrived. Excluding Farxiga and Brilinta, first-half revenue rose 11%.
Wainua then failed the CARDIO-TTRansform Phase III trial. Since that setback, U.S. regulators have approved Baxfendy for hypertension, Datroway in first-line triple-negative breast cancer, and new Enhertu and Imfinzi indications. Shares rose 5.42% over the past month to $172.19 but are still down 3.75% year to date.
Wall Street Expects Mid-Single-Digit Top-Line Growth
| Metric | Consensus | YoY Change |
|---|---|---|
| Q3 2026 EPS (per ADS) | $1.1457 | -3.7% |
| Q3 2026 Revenue | $16.0B | 5.3% |
| FY 2026 EPS | $10.05 | 9.7% |
| FY 2026 Revenue | $63.29B | 7.8% |
The Q3 EPS comparison converts last year’s core EPS of $2.38 per share to an ADS basis.
Oncology Depth and Farxiga Erosion Will Set the Tone
I’ll watch oncology first. Tagrisso grew only 7% last quarter, so Imfinzi, Enhertu and Calquence now do more of the work. Calquence exceeded $1 billion in quarterly revenue for the first time. Management puts peak sales for the stomach cancer drug sone-ve at $3 billion to $5 billion, and any commercial framing after ESMO matters.
Next is Farxiga. The second quarter was the first full quarter of U.S. generic competition, and Farxiga revenue came in at $1.80B. Whether respiratory products keep filling the gap is worth watching, after Breztri grew 22% and Fasenra 14%. China revenue fell 7% under volume-based procurement, which makes it another pressure point.
Margins come third. Management noted a lower second-half gross margin from seasonal products like FluMist and Beyfortus, plus higher finance costs. Net debt rose to $26.9B, and capex is set to rise by about a third this year.
Finally, the pipeline calendar. Management lists 25 key Phase III readouts over 18 months. SERENA-4, TROPION-Lung15 and SAFFRON are all due later in 2026.
A Chance to Prove the $80 Billion Path Still Holds
CEO Pascal Soriot said the “$80bn Total Revenue ambition” already assumes both successes and setbacks. History shows that beating estimates alone won’t move the stock for long. Across six beats, shares averaged a 1.7% day-of gain but just 0.05% over a week. A real breakout needs proof that new launches are outpacing patent losses.
Contact [email protected] for any questions or corrections.







